In conclusion, this case suggests that the application of molecularly targeted drugs to patients with genetic mutations after genetic testing for EGFR and ALK can significantly improve the prognosis of patients with PMEC, which is expected to be a new hope in the treatment of pulmonary mucoepidermoid carcinoma. This evidence concerns the gene EGFR and pulmonary mucoepidermoid carcinoma.